Current Press Release
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
LAWRENCE, KS – Deciphera Pharmaceuticals LLC (Lawrence, KS USA) announces the initiation of their IND Phase 1 trial for DCC-2036 on March 25, 2009, at MD Anderson Cancer Center in Houston. This Phase 1 study will evaluate the safety and tolerability of once a day continuous oral dosing of DCC-2036, a BCR-ABL kinase inhibitor, in patients with treatment resistant or intolerant Philadelphia chromosome positive chronic myeloid leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) including patients with the T315I gatekeeper amino acid mutation, for whom there remains a significant unmet medical need. This study will also enroll patients at Tufts Medical Center in Boston.
DCC-2036 is a tyrosine kinase inhibitor that is based on a proprietary ‘kinase switch pocket’ platform which designs small molecule inhibitors to constrain otherwise activated kinases in inactive conformational states. This approach has particular application in oncology, where kinases become conformationally activated by mutation. In addition to its inhibition of BCR-ABL, DCC-2036 also potently inhibits TIE2, LYN, HCK and FLT3 kinases, all of which are relevant to the treatment of myleoproliferative diseases.
About Deciphera
Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce "best-in-class" small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. Deciphera's kinase inhibitors target the mechanisms that render kinases oncogenic, retain potency against gatekeeper mutations, and afford selectivity profiles not easily attained by other approaches. For more information, visit the Company’s website at www.deciphera.com.
|
Media/News
April 7, 2009
October 3, 2008
October 3, 2008
March 24, 2008
August 30, 2007
September 20, 2004 - Chemical & Engineering News
December 18, 2003 - The Business Journal of Kansas City
April 12, 2003 - Lawrence Journal-World
February 11, 2003 - Lawrence Journal-World
|
pharmaceutical firm that moved to Lawrence from Cambridge, Mass., earlier
this year has raised $15 million from private Kansas investors. Deciphera
Pharmaceuticals, which is developing drugs to attack the molecular cause
of Alzheimer's disease, rheumatoid arthritis, asthma and other diseases...”
